Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramOfficers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.
Kurtz George0B / 217S · 10 late217 trades$54.77M| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 4 | Mehmel Robert FPresident and COO |  GFFGRIFFON CORPOpen-market sale · 10b5-1 plan | SELL | $89K 825 sh | Nov 6, 2026 |
| 4 | Brown Christopher D.Director |  MASS908 Devices Inc.Open-market sale · 10b5-1 plan | SELL | $329K 30.0K sh | Nov 6, 2026 traded Nov 4, 2026 |
| 3 | Rothblatt Martine ADirector, Chairperson & CEO |  UTHRUNITED THERAPEUTICS CorpOption exercise · 10b5-1 plan | M | — 9,500 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 3 | Zerbe Robert L MdDirector |  VCELVericel CorpOption exercise · 10b5-1 plan | M | $33K 2,500 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 3 | Michaelson JenniferChief Scientific Officer |  CGEMCullinan Therapeutics, Inc.Option exercise · 10b5-1 plan | M | — 3,805 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 2 | Urist MarshallEVP, Research & Investments |  RPRXRoyalty Pharma plcDerivative conversion | C | — 150.0K sh | Nov 6, 2026 traded Nov 6, 2026 |
| 2 | Pitofsky JasonSVP Controller |  REGNREGENERON PHARMACEUTICALS, INC.Option exercise | M | — 905 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 2 | Urist MarshallEVP, Research & Investments | RPRXRoyalty Pharma plc Grant or award | A | — 5,341 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 2 | Leach BryanDirector, CEO AND PRESIDENT, 10% Owner |  IBTAIbotta, Inc.Derivative conversion | C | — 13.3K sh | Nov 6, 2026 traded Nov 4, 2026 |
| 2 | Pitofsky JasonSVP Controller | REGNREGENERON PHARMACEUTICALS, INC. Option exercise | M | — 1,478 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 2 | Leach BryanDirector, CEO AND PRESIDENT, 10% Owner | IBTAIbotta, Inc. Derivative conversion | C | — 13.3K sh | Nov 6, 2026 traded Nov 4, 2026 |
| 2 | Peters William JDirector, CFO, EVP & TREASURER |  AMPHAmphastar Pharmaceuticals, Inc.Option exercise · 10b5-1 plan | M | $198K 11.0K sh | Nov 6, 2026 traded Nov 5, 2026 |
| 2 | Coxe TenchDirector |  NVDANVIDIA CORPGift · 10b5-1 plan | G | — 500.0K sh | Nov 6, 2026 traded Nov 4, 2026 |
| 2 | Magliulo VirginiaExecutive VP |  ADPAUTOMATIC DATA PROCESSING INCOption exercise · 10b5-1 plan | M | $176K 852 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 2 | Malady KyleEVP and Group CEO-VZ Business |  VZVERIZON COMMUNICATIONS INCGrant or award | A | $1,738 132 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 2 | Coyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Grant or award | A | — 7,122 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 2 | Coyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Derivative conversion | C | — 150.0K sh | Nov 6, 2026 traded Nov 6, 2026 |
| 2 | Coyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Derivative conversion | C | — 10.0K sh | Nov 6, 2026 traded Nov 6, 2026 |
| 2 | Coyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Derivative conversion | C | — 100.0K sh | Nov 6, 2026 traded Nov 6, 2026 |
| 1 | Hug JoshuaDirector |  RELYRemitly Global, Inc.Open-market sale · 10b5-1 plan | SELL | $122K 5,500 sh | Nov 6, 2026 traded Nov 6, 2026 |
| 1 | Rubinstein JuliePresident and COO | ADPTAdaptive Biotechnologies Corp Open-market sale · 10b5-1 plan | SELL | $229K 8,400 sh | Nov 6, 2026 traded Nov 6, 2026 |
| 1 | Rubinstein JuliePresident and COO | ADPTAdaptive Biotechnologies Corp Open-market sale · 10b5-1 plan | SELL | $103K 4,000 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 1 | Rubinstein JuliePresident and COO | ADPTAdaptive Biotechnologies Corp Open-market sale · 10b5-1 plan | SELL | $210K 7,881 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 1 | DIRK VAN DE PUTDirector, Chief Executive Officer |  MDLZMondelez International, Inc.Option exercise · 10b5-1 plan | M | $909K 20.9K sh | Nov 6, 2026 traded Nov 5, 2026 |
| 1 | Rubinstein JuliePresident and COO | ADPTAdaptive Biotechnologies Corp Open-market sale · 10b5-1 plan | SELL | $155K 5,926 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 1 | Rubinstein JuliePresident and COO | ADPTAdaptive Biotechnologies Corp Open-market sale · 10b5-1 plan | SELL | $147K 5,455 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 1 | O'Day Daniel PatrickDirector, Chairman & CEO |  GILDGILEAD SCIENCES, INC.Option exercise · 10b5-1 plan | M | $710K 9,810 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 1 | Rubinstein JuliePresident and COO | ADPTAdaptive Biotechnologies Corp Open-market sale · 10b5-1 plan | SELL | $97K 3,481 sh | Nov 6, 2026 traded Nov 6, 2026 |
| 1 | Hug JoshuaDirector | RELYRemitly Global, Inc. Open-market sale · 10b5-1 plan | SELL | $118K 5,500 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 0 | Vassil JonathanChief Revenue Officer |  TOSTToast, Inc.Option exercise · 10b5-1 plan | M | — 3,700 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 0 | Corbin Charles R. Jr.See Remarks |  HGVHilton Grand Vacations Inc.Option exercise · 10b5-1 plan | M | — 6,365 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 0 | Vassil JonathanChief Revenue Officer | TOSTToast, Inc. Option exercise · 10b5-1 plan | M | $64K 3,700 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 0 | Seidman Becker CarynDirector, Chief Executive Officer, 10% Owner |  YOUClear Secure, Inc.Disposition to issuer · 10b5-1 plan | D | — 176.1K sh | Nov 6, 2026 traded Nov 5, 2026 |
| 0 | Alclear Investments, LLCDirector, 10% Owner, See Remarks | YOUClear Secure, Inc. Option exercise · 10b5-1 plan | M | — 176.1K sh | Nov 6, 2026 traded Nov 5, 2026 |
| 0 | Rubinstein JuliePresident and COO | ADPTAdaptive Biotechnologies Corp Open-market sale · 10b5-1 plan | SELL | $14K 500 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 0 | Azar Samak LChief Legal Officer |  GFSGLOBALFOUNDRIES Inc.Open-market sale · 10b5-1 plan | SELL | $13K 335 sh | Nov 6, 2026 traded Nov 5, 2026 |
| 0 | Skates SpenserDirector, CEO and President, 10% Owner |  AMPLAmplitude, Inc.Derivative conversion · 10b5-1 plan | C | — 901 sh | Nov 6, 2026 traded Nov 4, 2026 |
| 0 | Patel Sanj KDirector, CHAIRMAN & CEO |  KNSAKiniksa Pharmaceuticals International, plcOption exercise · 10b5-1 plan | M | — 145.8K sh | Nov 6, 2026 traded Nov 4, 2026 |
| 0 | Alclear Investments, LLCDirector, 10% Owner, See Remarks | YOUClear Secure, Inc. Grant or award · 10b5-1 plan | A | — 176.1K sh | Nov 6, 2026 traded Nov 5, 2026 |
| 0 | Rubinstein JuliePresident and COO | ADPTAdaptive Biotechnologies Corp Option exercise · 10b5-1 plan | M | $144K 11.9K sh | Nov 6, 2026 traded Nov 6, 2026 |
DRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
FERGFerguson Enterprises Inc. /DE/Oct 12 – Oct 167 insiders$7.38M
SYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
UPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
IBEXIBEX LtdSep 14 – Sep 166 insiders$2.01M
ARQQArqit Quantum Inc.Oct 2 – Oct 136 insiders$369K
BBTBeacon Financial CorpOct 26 – Oct 306 insiders$274K
BCYCBICYCLE THERAPEUTICS PLCOct 2 – Oct 56 insiders$63K